Skip to main content
Publications
Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Apr 29. doi: 10.1007/s40273-024-01385-9
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Guh S, Chen XB, Poulos C, Qi Z, Cao JW, von Seidlein L, Chen JC, Wang XY, Xing ZC, Nyamete A, Clemens J, Whittington D. Comparison of cost-of-illness with willingness-to-pay estimates to avoid shigellosis: evidence from China. Health Policy Plan. 2008 Mar 1;23(2):125-36.
Canh DG, Whittington D, Thoa LTK, Utomo N, Hoa NT, Poulos C, Thuy DTD, Kim D, Nyamete A, Acosta C. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 2006 May 1;21(3):241-55.